Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Analyst Ratings

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.33 (2,893.20% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetActions
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/13/2016        
3/15/2016Q415($0.56)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215($0.38)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.43)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014($0.14)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.50)($0.46)$3.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:EPRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.66)($0.40)($0.53)
Q2 20162($0.52)($0.26)($0.39)
Q3 20162($0.43)($0.16)($0.30)
Q4 20162($0.27)($0.15)($0.21)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateHeadline
07/23/16 07:57 AMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 04:01 PMCurrent EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) PT Means Stock Is Worth Almost $2 - Review Fortune
07/21/16 07:22 AMLion Biotechnologies : Biotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies
07/21/16 07:22 AMBiotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies
07/20/16 06:14 AMBroker Outlook For EPIRUS Biopharmaceuticals, Inc. (EPRS) - Fiscal Standard
07/18/16 03:59 PMEpirus Biopharmaceuticals Inc (NASDAQ:EPRS): Down, But Perhaps Not Out - Insider Financial
07/15/16 06:29 AMHC Stocks Zone: Gilead Sciences, Inc. (NASDAQ:GILD), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release)
07/14/16 07:05 AMNews review of 2 biotech stocks: Galena Biopharma, Inc. (NASDAQ:GALE), EPIRUS Biopharmaceuticals, Inc ... - The Voice Registrar
07/14/16 07:05 AMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earns Consensus Hold Rating - Review Fortune
07/13/16 06:29 AMWhich way EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) insiders are heading - Review Fortune
07/13/16 06:29 AMAnalysts: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) stock is worth $2 - Review Fortune
07/12/16 09:13 PMInvestor Catching Stock: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - News Oracle
07/11/16 03:51 PM3 Notable Runners: EPIRUS Biopharmaceuticals, Inc. (EPRS), Johnson & Johnson (JNJ), Pandora Media, Inc. (P) - iStreetWire
07/11/16 08:38 AMStock Rating Watch and Earnings Insight for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Press Telegraph
07/11/16 08:38 AMEpirus Biopharmaceuticals Inc (NASDAQ:EPRS) & Nokia Corp (ADR) (NYSE:NOK) Stocks on the Move - Money News (press release)
07/10/16 08:22 AMNext Weeks Broker Price Targets For EPIRUS Biopharmaceuticals, Inc. (EPRS) - Fiscal Standard
07/09/16 07:20 AMCan EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 06:37 AMCompany Stock Focus for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Which Way Will Shares Head? - Press Telegraph
07/07/16 03:54 PMHC Stocks Highlights: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release)
07/07/16 06:22 AMSignificant Movements: Merck & Company, Inc. (NYSE:MRK) , EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Street Updates
07/06/16 03:57 PMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 03:57 PMUnusual Volume Recap: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Engelwood Daily
07/06/16 03:57 PMHC Stocks Summary: Galena Biopharma Inc (NASDAQ:GALE), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release)
07/06/16 03:57 PMWorthy Stock Update: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - News Oracle
07/06/16 08:35 AMDow Jones suffers triple-digit fall
07/06/16 08:35 AMUS stocks nurse losses as post-Brexit hurts oil prices
07/05/16 03:45 PMStocks Hitting 52-Week Lows - Benzinga
07/01/16 05:10 PMETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : July 1, 2016 -
07/01/16 04:23 PMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mate -
06/30/16 09:15 PMEpirus Biopharmaceuticals Incorporated (NASDAQ:EPRS) Shorted Shares Increased By 15.46% - Press Telegraph
06/28/16 08:53 PMHow Analysts Rated Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) Last Week? - Press Telegraph
06/28/16 08:53 PMNew Broker Ratings For EPIRUS Biopharmaceuticals, Inc. (EPRS) - FTSE News
06/28/16 08:53 PMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Company Rating and Target Watch - Telanagana Press
06/24/16 03:56 PMHC Stocks Alerts: Gilead Sciences, Inc. (NASDAQ:GILD), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release)
06/24/16 03:56 PMEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 10:40 AMCovering the Bases on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Where is the Stock Going? - Press Telegraph
06/24/16 10:40 AMAnalysts Observing Trading Stocks: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Baxter International Inc ... - Street Updates
06/21/16 03:38 PMHealthcare Bears: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), Innocoll Holdings plc (NASDAQ:INNL), Egalet ... - KC Register
06/21/16 11:57 AMETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : June 21, 2016 -
06/14/16 03:07 PMEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -
06/13/16 06:30 AM[$$] Billions at Stake as Biotech-Copycat Startups Chase Pharma Giants -
06/10/16 06:26 PMETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : June 10, 2016 -
06/05/16 07:32 AMPerformance report of the company: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - News Oracle
06/03/16 04:05 PMAnalyst Recommended Buy These Stocks: VeriFone Systems, Inc. (NYSE:PAY), EPIRUS Biopharmaceuticals, Inc ... - Beacon Chronicle
06/03/16 08:13 AMShare Rating Focus on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - HNN - Share Rating Focus on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNPresently, Wall Street analysts have given a consensus stock rating of 2.33 on shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
06/02/16 07:14 AMTarget Price and Stock Performance Rundown for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - HNN - Target Price and Stock Performance Rundown for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNDuring the latest trading session, EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) shares traded +17.72%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have ...and more »
06/01/16 10:09 PMStock Poised for a Rebound: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - HNN - Stock Poised for a Rebound: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNMany investors are considering shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) to be “oversold” as the commodity reached $0.62 on a recent tick. An oversold stock has a current price that an investor thinks is lower than the inherent value of ...
05/30/16 08:53 PMEPIRUS Biopharmaceuticals, Inc. (EPRS) Broker Price Targets For The Coming Week - Share Trading News - EPIRUS Biopharmaceuticals, Inc. (EPRS) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of EPIRUS Biopharmaceuticals, Inc. (EPRS). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...How Analysts Rated Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) Last Week?Franklin IndependentPerformance at a Glance on EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)HNNall 3 news articles »
05/28/16 01:47 PMRecent Movements of Stocks: Bruker Corporation (NASDAQ:BRKR) , EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Street Updates - Recent Movements of Stocks: Bruker Corporation (NASDAQ:BRKR) , EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)Street UpdatesEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) moved in red zone with decline of -0.06 points or -9.67% to $0.57. The company has a market worth of $14.92M.Total 658.56 thousand shares were exchanged in last trading session as opposed to average ...and more »
05/26/16 01:53 PMTarget Check and Stock Performance Recap EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Wall Street Hints and News - Target Check and Stock Performance Recap EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS)Wall Street Hints and NewsIn recent session activity, EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) shares have traded +6.588%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »

Social

About Epirus Biopharmaceuticals

Epirus Biopharmaceuticals logoEPIRUS Biopharmaceuticals, Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Company's lead product candidate, BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name, Infimab. The Company's products include BOW015, which contains infliximab; BOW050, which contains adalimumab; BOW070, which contains tocilizumab; BOW080, which contains eculizumab; BOW090, which contains ustekinumab, and BOW100, which contains golimumab.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPRS
  • CUSIP:
Key Metrics:
  • Previous Close: $0.25
  • 50 Day Moving Average: $0.443
  • 200 Day Moving Average: $1.981
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $6.42M
  • Beta: 2.75
  • Current Year EPS Consensus Estimate: $-2.16 EPS
Additional Links:
Epirus Biopharmaceuticals (NASDAQ:EPRS) Chart for Sunday, July, 24, 2016